Michael Bloch

Michael has also spent seven months on secondment in the ECM business team at Credit Suisse, and has previously worked on secondment at ExxonMobil.

“Rising Star” IFLR1000 2019 (Equity Capital Markets)

“‘Very technically savvy,’ ‘easy to work with’ and ‘a good, safe pair of hands.’” Chambers UK 2020 (Equity Capital Markets)

"He is really impressive" Chambers UK 2021 (Capital Markets: Equity)

"He has good experience and he's a nice guy to deal with" Chambers UK 2021 (Capital Markets: Equity)

"Next Generation Partner" Legall 500 UK 2021 (Equity Capital Markets - Mid-High Cap)

Other noteworthy experience includes advising:

• Kuwait Energy on its USD650m acquisition by United Energy Group by way of scheme of arrangement.
• McCarthy & Stone on its GBP388m IPO on the premium main market of the London Stock Exchange (issuer's counsel)
• Tullet Prebon on its reverse takeover acquisition of the global hybrid voice-broking and information business of ICAP plc.
• Cobham on its GBP500m and GBP512m rights issues on the London Stock Exchange (issuer's counsel)
• Equinity on its GBP317m IPO on the premium main market of the London Stock Exchange (underwriters counsel)
• Circassia Pharmaceuticals ont its GBP580m IPO on the premium main market of the London Stock Exchange and GBP275m placing and open offer in connection with the acquisitions of Aerocrine and Prosonix (issuer's counsel).
• Softcat on its GBP153m IPO on the premium main market of the London Stock Exchange (underwriter's counsel)
• Spire Healthcare on its GBP842m IPO on the premium main market of the London Stock Exchange (underwriter's counsel)
• Sensyne Health a digital healthcare company that develops regulated medical products and services using artificial intelligence, on its GBP225m IPO on the London Stock Exchange's AIM market.
• Medopad on its Series A funding round to develop its healthcare technology data-capture platform.